Jump to content

Pasireotide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 07:28, 30 January 2018 (Wikilinks). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pasireotide
Clinical data
Trade namesSignifor
Other namesSOM230
License data
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ECHA InfoCard100.211.883 Edit this at Wikidata
Chemical and physical data
FormulaC58H66N10O9
Molar mass1047.21 g/mol[1] g·mol−1
3D model (JSmol)
  • C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
  • InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1 ☒N
  • Key:VMZMNAABQBOLAK-DBILLSOUSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the United States[3] and Europe[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Pasireotide was approved for Cushing's disease by the EMA in October 2009[7] and by the FDA in December 2012.[8]

Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA one month earlier.[9]

References

  1. ^ Pasireotide | C58H66N10O9 - PubChem https://pubchem.ncbi.nlm.nih.gov/compound/Pasireotide
  2. ^ Signifor® (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/
  3. ^ http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200677lbl.pdf
  4. ^ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf
  5. ^ "Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease". Retrieved 2012-07-08. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  6. ^ Mancini, Tatiana; Porcelli, Teresa; Giustina, Andrea (2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. doi:10.2147/TCRM.S12952. PMC 2963160. PMID 21063461.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  7. ^ EMEA Approval for Pasireotide
  8. ^ "FDA Approves Pasireotide for Cushing's Disease".
  9. ^ Tucker, Miriam E. FDA Approves Pasireotide for Treating Acromegaly, Medscape, December 17, 2014, Retrieved 2015-08-21



Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pasireotide&oldid=823102870"